Stocks · News reference
Jazz Pharmaceuticals Raises FY2026 Sales Guidance from $4.250B-$4.500B to $4.600B-$4.750B vs $4.517B Est
Jazz Pharmaceuticals (NASDAQ:JAZZ) raises FY2026 sales outlook from $4.250 billion-$4.500 billion to $4.600 billion-$4.750 billion vs $4.517 billion estimate.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 3, 2026, 8:11 PM
- Checked
- Aug 3, 2026, 8:11 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Deutsche Bank Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $300
Deutsche Bank analyst David Hoang maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the price target from $287 to $300.
Read original at benzingaMorgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $322
Morgan Stanley analyst Jeffrey Hung maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $283 to $322.
Read original at benzingaThese Analysts Increase Their Forecasts On Jazz Pharmaceuticals
FDA approves JAZZ's Ziihera-containing combination regimens for HER2-positive gastroesophageal adenocarcinoma. JAZZ stock drops 0.8% to $258.14. Analysts raise price targets to $310 and $281 in response to positive earnings. Considering buying JAZZ? Here's what analysts say.
Read original at benzinga